REPORT ID 13714

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Research Report 2017

Publish Date
22-Nov-17
Pages
103
Format
Electronic (PDF)

In this report, the global Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Resistant Pseudomonas Aeruginosa Infections Drugs in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global Resistant Pseudomonas Aeruginosa Infections Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    ContraFect Corp
    Inhibrx LP
    Achaogen Inc
    LegoChem Biosciences Inc
    Melinta Therapeutics Inc
    Novartis AG
    AmpliPhi Biosciences Corp
    Biolytics Pharma
    Shionogi & Co Ltd
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Semi-Synthetic Penicillin
    Cephalosporin
    Lactam Drugs
    Others
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Research Report 2017
1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview
    1.1 Product Overview and Scope of Resistant Pseudomonas Aeruginosa Infections Drugs
    1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type (Product Category)
        1.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Market Share by Type (Product Category) in 2016
        1.2.3 Semi-Synthetic Penicillin
        1.2.4 Cephalosporin
        1.2.5 Lactam Drugs
        1.2.6 Others
    1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application
        1.3.1 Resistant Pseudomonas Aeruginosa Infections Drugs Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market by Region (2012-2022)
        1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of Resistant Pseudomonas Aeruginosa Infections Drugs (2012-2022)
        1.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Status and Outlook (2012-2022)
        1.5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production Status and Outlook (2012-2022)

2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Manufacturers
    2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production and Share by Manufacturers (2012-2017)
    2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Share by Manufacturers (2012-2017)
    2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Resistant Pseudomonas Aeruginosa Infections Drugs Market Competitive Situation and Trends
        2.5.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Rate
        2.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity and Market Share by Region (2012-2017)
    3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production and Market Share by Region (2012-2017)
    3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Consumption by Region (2012-2017)
    4.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)
    4.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)
    4.4 China Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)
    4.5 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)
    4.7 India Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption, Export, Import (2012-2017)

5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue (Value), Price Trend by Type
    5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production and Market Share by Type (2012-2017)
    5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2012-2017)
    5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2012-2017)
    5.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Growth by Type (2012-2017)

6 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Analysis by Application
    6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Consumption and Market Share by Application (2012-2017)
    6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Profiles/Analysis
    7.1 ContraFect Corp
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Inhibrx LP
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Achaogen Inc
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 LegoChem Biosciences Inc
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Melinta Therapeutics Inc
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Novartis AG
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 AmpliPhi Biosciences Corp
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Biolytics Pharma
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview
    7.9 Shionogi & Co Ltd
        7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.9.4 Main Business/Business Overview

8 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Cost Analysis
    8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2017-2022)
    12.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price and Trend Forecast (2017-2022)
    12.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer